Kornimate/medical-research-clean huggingface dataset:
duchenne muscular dystrophy heart study

Conditions: Duchenne Muscular Dystrophy; Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy

Summary: retrospective cohort study including patients with genetically proven duchenne muscular dystrophy, diagnosed from january 1993 to march 2020. inclusion of the data relative to genetic diagnosis, clinical characteristics at baseline, cardiac and respiratory workup, medical treatments (ace inhibitors, steroids), surgical procedures, and occurrence during follow-up of cardiac, respiratory and fatal events. objectives are to describe long-term natural history of the disease, vital prognosis, genotype-phenotype correlations, effect of treatments.


Eligibility criteria:
inclusion criteria: * genetically-proven duchenne muscular dystrophy (dmd mutation) * covering by social security exclusion criteria: * patient refusal to participate to the study
evaluation of local capillary blood lactate in chronic critical ischemia of lower limb before and after revascularization

Conditions: Chronic Critical Ischemia

Summary: evaluation of a new biological criterion, the local capillary blood lactates to optimize the management of patients with chronic critical ischemia requiring revascularization fast. potential use in terms of capillary blood lactate as a diagnostic indicator of recurrent ischemia in a limb revascularized.


Eligibility criteria:
inclusion criteria: * ischemia chronic critical lower limb revascularization procedure requiring fast. * written consent informed patient age greater than or equal to 18 exclusion criteria: * presence of an inflammatory or infectious (erysipelas) in the ischemic member. * patients at risk for diabetic foot ie, as defined by the has (preventing diabetic foot, 2007) * presence of sensory neuropathy, and / or * foot deformities (hallux valgus, hammer toes or claw, prominence of the metatarsal heads), and / or * history of foot ulceration, and / or * antecedent of one of these factors (ie antécedant diabetic foot). * necrosis of the toes. * participation in another clinical research protocol. * presence of peripheral arterial disease in the bilateral upper limbs. * patient in shock whatever the cause. * presence of hepatic failure. * too impaired general condition (bedridden, dementia, ...) * refusal of the patient to participate in the study * protected patients
observational study of donepezil in routine clinical practice

Conditions: Alzheimer's Disease

Summary: to characterize the comorbidities and medications of patients treated with donepezil in a routine clinical practice and to verify the therapeutic response of these patients.

this trial was terminated prematurely on december 31, 2007 due to difficulties in enrolling patients in the study. there were no safety or efficacy concerns regarding the study in the decision to terminate the trial.

Eligibility criteria:
inclusion criteria: * dsm-iv criteria for the clinical diagnosis of mild to moderate alzheimer's disease with or without other etiologies of dementia * mini mental status examination score of 10-26 exclusion criteria: * contraindication as stated in the canadian label for donepezil * subjects treated with medication for dementia within 30 days prior to baseline

Keywords: alzheimer's disease, naturalistic study
pape effect with blood flow restriction and push-up exercise (post-activation performance enhancement)

Conditions: Blood Flow Restriction Exercise

Summary: this study aims to compare the acute effects of push-up exercises performed under different blood flow restriction (bfr) conditions on upper extremity explosive strength performance, measured via the seated unilateral medicine ball throw test.

the study includes three push-up conditions (bfr, sham bfr, and no bfr). performance is evaluated via medicine ball throws at the 4th, 8th, and 12th minutes post-exercise. exercises are applied in a crossover design with 50% limb occlusion pressure (lop) bfr, sham, and control arms. throw distance and ball velocity (measured by radar device) are primary outcomes. rpe scale is used to assess perceived exertion.

Eligibility criteria:
inclusion criteria: * being between 18 and 25 years old * being a volleyball player * having trained regularly in the last 6 months * ability to perform at least 5 repetitions of push-up with own body weight * voluntarily agreeing to participate and signing the informed consent form exclusion criteria: * history of shoulder or upper extremity injury requiring physical therapy or surgery * history of venous thromboembolism * hematological disorders * coronary artery disease * peripheral arterial disease * hypertension (systolic/diastolic \> 140 mmhg/90 mmhg) * history or high risk of deep vein thrombosis * blood clotting disorders * poor circulation * inadequate lymphatic system * history of endothelial dysfunction * varicose veins * peripheral vascular disease * diabetes * easy bruising * active infection * cancer * renal failure * pregnancy * intolerance to intervention

Keywords: bfr push-up exercise pape radar measurement explosive power
health status and its socio-economic covariates of the older population in poland - the nationwide polsenior2 survey.

Conditions: Aging Disorder; Age Problem; Healthy Aging; Immunity Disorders; Frailty Syndrome; Behaviors, Health; Health Care Utilization

Summary: the polsenior2 survey is aimed to characterise health status of old and very-old adults in poland.

one of the goals is assessing the prevalence and control of age-related diseases and of the "geriatric giants" (immobility, instability, incontinence, sensory deficiency, cognition and mood disorders) which lead to frailty, disability and dependence. monitoring of health status, health behaviors and identifying socio-economic factors favoring successful aging will be significant. as the polypragmasy and adverse drug reactions remain a significant issue in the geriatric care, pharmacotherapy and medical adherence will also be examined. the additional purpose of the study is to evaluate the utilization and access to health care and social services in respect to needs for assistance and long-term care, as well as the level and different forms of these needs. the project is planned as a cross-sectional survey of representative sample of 6000 people aged 60 years and over. the study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, anthropometric and blood pressure measurements and laboratory tests. the data are collected by well-trained nurses during three visits at respondents homes.

Eligibility criteria:
inclusion criteria: * over 60 years of age, * randomly selected from database of all polish citizens, * consent to participate in the study. exclusion criteria: * under 60 years of age, * no consent to participate in the study.
bumetanide vs. furosemide in cirrhosis

Conditions: Cirrhosis

Summary: patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. in patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. in this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.


Eligibility criteria:
inclusion criteria: * history of liver cirrhosis * clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital exclusion criteria: * allergy to bumetanide or furosemide * contraindication to diuretic administration (e.g. active bleeding, clinical suspicion of hepatorenal syndrome, hypotension) * incarcerated or in custody of law enforcement * diuretic ordered for purpose other than volume overload (e.g. hyperkalemia, continuation of home medication without clinical signs of volume overload) * inpatient admission not anticipated * not admitted to an inpatient hospital bed following initial evaluation in the emergency department

Keywords: cirrhosis volume overload diuresis furosemide bumetanide
steroid aromatase inhibitors versus progestogens for nsaid-resistanced late stage breast cancer

Conditions: Carcinoma Breast Stage IV

Summary: steroid aromatase inhibitors and non-steroid aromatase inhibitors in late stage breast cancer is the recommended scheme in national comprehensive cancer network (nccn) guideline. in the past controlled clinical trials with small sample.

a randomized study of steroid aromatase inhibitors versus progestogens for non-steroid aromatase inhibitor-resistanced late stage breast cancer.the primary endpoints of the study is progression free survival (pfs). the secondary endpoints are overall response rate (orr), overall survival (os) and safety.

Eligibility criteria:
inclusion criteria: 1. patients must be the postmenopausal women 2. patients must be diagnosed with advanced breast cancer by imageology，cytology or histopathology 3. immunohistochemistry shows er and/or pr positive 4. patients ecog score must be 0-2 5. drug resistant about non-steroid aromatase inhibitors exclusion criteria: 1. not suitable for endocrine therapy 2. have receive the standard steroid aromatase inhibitors treatment 3. severe hepatic dysfunction

Keywords: said, progestogens, nsaid-resistanced, lsbc
tooth development in molar incisor hypomineralisation

Conditions: Molar Incisor Hypomineralization

Summary: molar incisor hypomineralization has been defined as a qualitative developmental enamel defect affecting one or more permanent first molars, often including the permanent incisors. the development of the teeth with the developmental defect remains unclear. the aim of this study is to evaluate tooth development in children with mih using the cameriere and haavikko methods on panoramic radiographs and to determine the accuracy of these methods. the first null hypothesis of this study was that there would be no difference in tooth development between children with mih and children with healthy structure of teeth, and the second null hypothesis was that cameriere and haavikko methods could estimate dental age with the equal accuracy.

this study was planned to evaluate tooth development in a cohort of 8- to 12-year-old children diagnosed with mih who applied to the department of pedodontics, faculty of dentistry, tokat gaziosmanpaşa university, for dental examinations or treatment between june 1, 2023, and june 1, 2024. the study group (group 1) was determined according to gender and chronological age group from children who were diagnosed with mih as a result of dental examination and met the inclusion criteria. the control group (group 2) was selected from children matched to mih cases according to gender and chronological age, without signs of hypomineralisation and met the inclusion criteria. the chronological age of the children was calculated using microsoft excel 2013 (microsoft, redmond, wa, usa). the following formula was applied: "\[(date of panoramic radiography) - (documented date of birth)\] / 365.25" tooth development was determined on panoramic radiographs taken with a single device (j. morita mfg. corp., kyoto, japan) using the cameriere and haavikko methods. the data were analyzed using the ibm statistical package for the social sciences (spss for windows, version 26.0, spss inc., chicago, il, usa). data from the two dental age estimation methods were analyzed for each gender and age group within group 1 and group 2. the kolmogorov-smirnov test was applied to assess normality. the spearman correlation coefficient was employed to examine the relationship between chronological and dental age, and the paired samples t-test and wilcoxon signed-rank test were used to compare the difference. the independent samples t-test and mann-whitney u test were utilized to compare chronological and dental age based on mih presence. intraclass correlation coefficient (icc) was calculated to assess inter- and intra-observer reliability. quantitative data are presented as mean ± standard deviation and median (minimum-maximum), while categorical data are presented as frequency (percentage). statistical significance was set at the 0.05 level.

Eligibility criteria:
inclusion criteria: must have parental consent must have high-quality panoramic radiographs exclusion criteria: systemic disease tooth agenesis hyperdontia

Keywords: children dental age estimation dental development
cortisone treatment for the prevention of postoperative pancreatitis and pancreatitis-induced complications after pancreaticoduodenectomy and distal pancreatic resection

Conditions: Postoperative Complications; Postoperative Pancreatitis

Summary: the purpose of this randomized, placebo-controlled trial is to investigate whether postoperative pancreatitis and other immediate complications after pancreaticoduodenectomy or distal pancreatic resection may be reduced with cortisone treatment. treatment is administered to high risk patients (defined by high amount of acinar cells in the cut edge of pancreas).


Eligibility criteria:
inclusion criteria: * pancreaticoduodenectomy and distal pancreatectomy patients in tampere university hospital exclusion criteria: * patients with an ongoing cortisone treatment * cefuroxime allergy * chronic pancreatitis

Keywords: postoperative pancreatitis postoperative complications delayed gastric emptying leakage fistula acinar cell risk patient pancreaticoduodenectomy whipple cortisone
effect of intranasal breast milk administration in preterm infants

Conditions: Newborn; Vitality; Nursing Caries; Breast Feeding

Summary: the aim of the study was to investigate the effect of intranasal breast milk administration on cerebral oxygenation level, vital signs and time to full oral feeding in preterm infants.

breast milk is rich in pluripotent stem cells, including pluripotent stem cells that produce neuronal cells in vitro. therefore, intranasal breast milk administration in neonates may potentially allow the transport of stem cells and other molecules into brain tissue through the nasal vasculature and permeable neonatal blood-brain barrier. in recent years, studies on intranasal breast milk administration in newborns have been published. in studies, there is evidence that intranasal breast milk may be effective in reducing cerebral damage after intracranial hemorrhage in preterm newborns and that the application can be tolerated by preterm newborns.

Eligibility criteria:
inclusion criteria: * birth weight \>1000 gr, * apgar score \>7 at 5 minutes after birth, * availability of breast milk, * no medical diagnosis affecting cerebral oxygenation (intraventricular hemorrhage, cardiovascular and neurological disorders, anemia), * no congenital anomalies or chromosomal abnormalities, * no congenital anomaly (such as cleft palate) affecting nasal patency. exclusion criteria: * being able to feed orally in all feedings * being fed entirely on formula milk, * administration of medication via the nasal route, * being intubated or receiving continuous positive air pressure (cpap) support, * maternal substance abuse, alcohol abuse, hiv infection, untreated active tuberculosis, chemotherapy or radiotherapy treatment, * the mother has mastitis, breast trauma, abscesses or is taking any medication that passes into the milk, * the mother does not want to express milk.

Keywords: breast milk newborn nursing oral nutrition physiological parameters preterm infant
evaluation of the child and family traumatic stress intervention

Conditions: Posttraumatic Stress Disorder

Summary: the purpose of this study is to determine the efficacy of the child and family traumatic stress intervention (cftsi) in preventing the development of posttraumatic stress disorder (ptsd) when implemented within 30 days of a potentially traumatic event.


Eligibility criteria:
inclusion criteria: * youth exposed to a potentially traumatic event within the last 30 days who have one new symptom on the posttraumatic checklist (pcl) exclusion criteria: * already receiving mental health treatment * autism or developmental disability * diagnosed with psychosis or bipolar disorder * non-english speaking

Keywords: school age children and adolescents exposed to a potentially traumatic event
mix vaccine for metastatic sarcoma patients

Conditions: Metastatic Sarcoma; Reaction - Mixed Vaccine

Summary: the aim of this study is the safety and efficacy of mix vaccine to small metastases of sarcoma.

by enrolling patients with small metastases of sarcoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine. the safety will be evaluated by statistics of adverse reactions. the efficacy will be evaluated according to local relief degree, progress free survival (pfs) and overall survival (os).

Eligibility criteria:
inclusion criteria: * all standard therapies have failed according to nccn guidelines or the patient refuses standard therapies after cancer recurrence * body tumor 1-6, the maximum tumor length \< 2 cm * kps ≥ 70, lifespan \> 6 months * platelet count ≥ 80×109/l，white blood cell count ≥ 3×109/l, neutrophil count ≥ 2×109/l, hemoglobin ≥ 80 g/l exclusion criteria: * patients with cardiac pacemaker * patients with brain metastasis * patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
a china rws to evaluate the effectiveness and safety of perampanel as an add-on treatment for epileptic seizure

Conditions: Epilepsy

Summary: this study is a real-word clinical trial. the purpose of this study is to evaluate the effectiveness and safety of perampanel as an add-on treatment for epileptic seizure. the enrolled subjects were epilepsy patients who had failed clinical treatment with 1-3 anti-epileptic drugs (aeds) with the optimal dose and course of treatment and needed additional treatment. the study was a real-world prospective clinical study, and the initial and maximum doses of perampanel were individualized by neurologists according to the patient's clinical situation.

this is a multi-center, prospective, observational study. subjects who meet all of the inclusion and none of the exclusion criteria will be received perampanel. baseline seizure counts (frequency) data is collected by subjects or guardian/legally authorized representative, retrospectively. it is expected to enroll 600 patients with epilepsy who are eligible for inclusion enrollment and receiving perampenal from january 2021 to october 2021. the initial and maximum doses of perampanel were individualized by neurologists according to the patient's clinical situation. the patients were followed up for 6 months and recorded the frequency of seizures and self-assessment of improvement. safety will be assessed by monitoring and recording of all of aes and serious adverse events (saes), discontinuation during 6 months treatment (patient spontaneous reporting).

Eligibility criteria:
inclusion criteria: * within 1 year before taking perampanel, the frequency of epileptic seizures was ≥1 time/month on average; * 1-3 kinds of aeds have been used, and the optimal dose and course of treatment have been reached, but the effect is not good. perampanel is used as an additional treatment; * follow up for at least 3 months; * sign informed consent (if necessary). exclusion criteria: * patients who have participated in other researches on antiepileptic drugs or medical devices; * inaccurate or unreliable clinical records according to the judgment of participating doctors; * when the database is closed, the expected follow-up time is less than 6 months.

Keywords: epilepsy perampanel
evaluation of scout ds device in the diagnosis of diabetes mellitus

Conditions: Type 2 Diabetes

Summary: the primary objective is to identify compare scout ds to random capillary glucose for identification of at-risk subjects with dysglycemia defined by hemoglobin a1c ≥ 6.0%.

the study will complete up to 400 subjects at the clinical site to evaluate the precision and accuracy of scout ds and random capillary glucose for detecting pre-diabetes and undiagnosed type 2 diabetes in subjects at risk but not having a pre-existing diagnosis of type 2 diabetes. a point of care a1c measurement will serve as the reference method for defining pre-diabetes (6.0% ≤ a1c ≤ 6.4%) and diabetes (a1c ≥ 6.5%). the study will require one visit by each subject to the clinical site. the visit does not require fasting and can be done any time of day. the study (not including the irb process and recruiting) is expected to last 6 months. the target cohort for comprises persons at risk for pre-diabetes and/or type 2 diabetes.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 45 years or age 18 to 44 years and with one or more of the following risk factors: * bmi \> 25 kg/m² * elevated waist circumference, \> 35 inches for women and \>40 inches for men * habitually physically inactive (does not exercise regularly) * has a first-degree relative with diabetes * ethnicity with elevated risk for type 2 diabetes * has delivered a baby weighing \> 9 lb or diagnosed with gestational diabetes * hypertension (≥130/≥ 85 mmhg) or being treated for hypertension * hdl cholesterol level \< 35 mg/dl and/or a fasting triglyceride level ≥ 250 mg/dl or being treated for dyslipidemia with medication * has been previously diagnosed with polycystic ovary syndrome (pcos) * had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 yrs * conditions associated with insulin resistance such as acanthosis nigricans * history of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease exclusion criteria: * • under 18 years of age * receiving investigational treatments in the past 14 days * psychosocial issues that interfere with an ability to follow study procedures * conditions that cause secondary diabetes including cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis * diagnosed with any type of diabetes, including type 1 or 2 * taking glucose lowering medications with the exception of metformin * known to be pregnant * receiving dialysis or having known renal compromise * scars, tattoos, rashes or other disruption/discoloration on the left volar forearm. * recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded * current chemotherapy, or chemotherapy within the past 12 months * receiving medications that fluoresce\* * known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)

Keywords: screening for type 2 diabetes